EGFR and non-small cell lung carcinoma: Activating alterations of human epidermal growth factor receptor 2 (HER2, also known as ERBB2), a member of the ErbB receptor tyrosine kinase family, have been identified as oncogenic drivers, occurring in 2–4% in non-small cell lung cancer (NSCLC) (Stephens et al., 2004; Arcila et al., 2012; Mazières et al., 2013; Peters and Zimmermann, 2014; Kris et al., 2015).